BIOMAT Database Logo BIOMAT Database Logo

Immunogenicity of liposome-associated and refined antigen oral cholera vaccines in Thai volunteers. 1998

W Chaicumpa, and M Chongsa-nguan, and T Kalambaheti, and P Wilairatana, and P Srimanote, and Y Makakunkijcharoen, and S Looareesuwan, and Y Sakolvaree
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

A mixture of Vibrio cholerae antigens made up of crude fimbrial extract, lipopolysaccharide and procholeragenoid was administered orally to Thai volunteers either as free antigen or associated with liposomes. All vaccines and controls were administered in three doses given at 14 day intervals. Nine volunteers received liposome-associated vaccine and seven received free vaccine. Liposomes without antigens were given to eight volunteers and seven volunteers received 5% NaHCO3 solution alone. Both vaccines had 100% immunogenicity as determined by serum vibriocidal antibody responses. Liposomes were shown by indirect ELISA to localize the immune response against lipopolysaccharide and fimbriae to the intestinal mucosa. Vaccines given liposome-associated antigens had a higher rate of antigen-specific antibody response than did individuals who had received free antigens. The vaccines induced intestinal antibodies of IgM and/or IgA isotypes, but not IgG antibody.

UI MeSH Term Description Entries
D007132 Immunoglobulin Isotypes The classes of immunoglobulins found in any species of animal. In man there are nine classes that migrate in five different groups in electrophoresis; they each consist of two light and two heavy protein chains, and each group has distinguishing structural and functional properties. Antibody Class,Ig Isotype,Ig Isotypes,Immunoglobulin Class,Immunoglobulin Isotype,Antibody Classes,Immunoglobulin Classes,Class, Antibody,Class, Immunoglobulin,Classes, Antibody,Classes, Immunoglobulin,Isotype, Ig,Isotype, Immunoglobulin,Isotypes, Ig,Isotypes, Immunoglobulin
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D008297 Male Males
D002771 Cholera An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is VIBRIO CHOLERAE. This condition can lead to severe dehydration in a matter of hours unless quickly treated. Vibrio cholerae Infection,Choleras,Infection, Vibrio cholerae,Infections, Vibrio cholerae,Vibrio cholerae Infections
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000907 Antibodies, Bacterial Immunoglobulins produced in a response to BACTERIAL ANTIGENS. Bacterial Antibodies

Related Publications

W Chaicumpa, and M Chongsa-nguan, and T Kalambaheti, and P Wilairatana, and P Srimanote, and Y Makakunkijcharoen, and S Looareesuwan, and Y Sakolvaree
Reactogenicity and immunogenicity of oral cholera vaccine in Thai volunteers.
September 1988, The Southeast Asian journal of tropical medicine and public health,
W Chaicumpa, and M Chongsa-nguan, and T Kalambaheti, and P Wilairatana, and P Srimanote, and Y Makakunkijcharoen, and S Looareesuwan, and Y Sakolvaree
IMMUNOGENICITY OF CHOLERA VACCINES.
August 1964, The Indian journal of medical research,
W Chaicumpa, and M Chongsa-nguan, and T Kalambaheti, and P Wilairatana, and P Srimanote, and Y Makakunkijcharoen, and S Looareesuwan, and Y Sakolvaree
Enhancement by lipid A of mucosal immunogenicity of liposome-associated cholera toxin.
January 1984, Reviews of infectious diseases,
W Chaicumpa, and M Chongsa-nguan, and T Kalambaheti, and P Wilairatana, and P Srimanote, and Y Makakunkijcharoen, and S Looareesuwan, and Y Sakolvaree
Pasteur oral cholera vaccine: studies of reactogenicity, clinical acceptability and immunogenicity in human volunteers.
March 1993, The Southeast Asian journal of tropical medicine and public health,
W Chaicumpa, and M Chongsa-nguan, and T Kalambaheti, and P Wilairatana, and P Srimanote, and Y Makakunkijcharoen, and S Looareesuwan, and Y Sakolvaree
Oral cholera vaccines.
September 1986, Lancet (London, England),
W Chaicumpa, and M Chongsa-nguan, and T Kalambaheti, and P Wilairatana, and P Srimanote, and Y Makakunkijcharoen, and S Looareesuwan, and Y Sakolvaree
Parameters affecting the immunogenicity of a liposome-associated synthetic hexapeptide antigen.
January 1991, European journal of immunology,
W Chaicumpa, and M Chongsa-nguan, and T Kalambaheti, and P Wilairatana, and P Srimanote, and Y Makakunkijcharoen, and S Looareesuwan, and Y Sakolvaree
Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine.
October 2010, BMC biology,
W Chaicumpa, and M Chongsa-nguan, and T Kalambaheti, and P Wilairatana, and P Srimanote, and Y Makakunkijcharoen, and S Looareesuwan, and Y Sakolvaree
Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers.
January 1992, Vaccine,
W Chaicumpa, and M Chongsa-nguan, and T Kalambaheti, and P Wilairatana, and P Srimanote, and Y Makakunkijcharoen, and S Looareesuwan, and Y Sakolvaree
Oral vaccines against cholera.
June 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
W Chaicumpa, and M Chongsa-nguan, and T Kalambaheti, and P Wilairatana, and P Srimanote, and Y Makakunkijcharoen, and S Looareesuwan, and Y Sakolvaree
Health status of Thai volunteers in a cholera vaccine trial.
October 1990, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
Copied contents to your clipboard!